Press Release Highlights

05.14.2013
Syndax Pharmaceuticals Announces Publication of Clinical Study Demonstrating that Entinostat Targets Resistance Pathways in Breast Cancer

05.09.2013
Syndax Pharmaceuticals to Commercialize First-in-Class Lung Cancer Treatment Developed at the University of Colorado

05.29.2012
Syndax Pharmaceuticals to Present Updated Overall Survival Data With Entinostat in Metastatic Breast Cancer at ASCO

05.16.2012
Syndax Pharmaceuticals Appoints Luke Evnin, Ph.D. to Board of Directors

04.30.2012
Syndax Pharmaceuticals Announces Publication of Entinostat Phase 2 Clinical Trial Data in Journal of Clinical Oncology

04.18.2012
Syndax Pharmaceuticals Appoints Arlene Morris as CEO

04.09.2012
Syndax Pharmaceuticals Announces Start of Phase 1/2 Study of Entinostat in Combination with Lapatinib in HER2-Positive Metastatic Breast Cancer

04.05.2012
Syndax Pharmaceuticals Appoints Arthur M. Pappas to Board of Directors

03.29.2012
Syndax Pharmaceuticals to Present at Upcoming Conferences

02.09.2012
Syndax Pharmaceuticals Announces Entinostat Enhanced Activity of Cancer Immunotherapies in Renal and Prostate Cancer Models

01.05.2012
Syndax Pharmaceuticals Signs Agreement with Ventana Medical Systems, Inc. to Develop Companion Diagnostic Test for Entinostat

12.11.2011
Entinostat Demonstrates Activity in Hodgkin’s Lymphoma

12.07.2011
Survival Benefit With Syndax Pharmaceuticals’ Entinostat Maintained in Women with Advanced Breast Cancer

11.09.2011
Epigenetic Therapy Shows Promise in Hard-to-treat Lung Cancer

2013 Archived Press Releases

2012 Archived Press Releases

2011 Archived Press Releases

2010 Archived Press Releases

Older Archived Press Releases

For media inquiries please email info@syndax.com.